Document Detail


Vascular Endothelial Growth Factor Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model.
MedLine Citation:
PMID:  23150613     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: This study sought to determine whether a Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-specific morpholino (MO) could decrease neovascularization, thereby enhancing murine cornea transplant survival, and if this effect is synergistic with steroid therapy.
METHODS: Graft survival, corneal neovascularization, and corneal lymphangiogenesis were compared among the VEGFR1_MO, STD MO and PBS groups following subconjunctival injection in mice that underwent normal risk penetrating keratoplasty (NR PK) and high-risk penetrating keratoplasty (HR PK). Graft survival, corneal neovascularization, and corneal lymphangiogenesis in groups treated with both VEGFR1_MO and steroid therapy were also analyzed in HR PK.
RESULTS: In NR PK, the VEGFR1_MO decreased angiogenesis, lymphangiogenesis, and increased graft survival compared with the PBS group (P = 0.055, P = 0.003, P = 0.043, respectively). In HR PK, VEGFR1_MO decreased angiogenesis, lymphangiogenesis, and increased graft survival compared with the STD MO (P = 0.000, P = 0.000, P = 0.029, respectively) and PBS groups (P = 0.004, P = 0.002, P = 0.024). In HR PK, when the VEGFR1_MO was combined with steroid therapy, a significant increase in graft survival was seen compared with steroid treatment alone (P = 0.045). The 2-month graft survival rate for HR PK was 27% in the combination group compared with 0% in the triamcinolone only group.
CONCLUSIONS: VEGFR1_MO decreased angiogenesis and lymphangiogenesis, resulting in increased graft survival in both NR PK and HR PK. This beneficial effect is synergistically enhanced with steroid treatment in HR PK.
Authors:
Yang Kyung Cho; Xiaohui Zhang; Hironori Uehara; Jason R Young; Bonnie Archer; Balamurali Ambati
Related Documents :
2977263 - Zoladex as primary therapy in advanced prostatic cancer. a french cooperative trial.
21677453 - Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancr...
9234923 - Phase ii trial of high-dose cisplatin plus ifosfamide as first-line followed by carbopl...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-12-19
Journal Detail:
Title:  Investigative ophthalmology & visual science     Volume:  53     ISSN:  1552-5783     ISO Abbreviation:  Invest. Ophthalmol. Vis. Sci.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-20     Completed Date:  2013-02-14     Revised Date:  2013-05-15    
Medline Journal Info:
Nlm Unique ID:  7703701     Medline TA:  Invest Ophthalmol Vis Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  8458-71     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cornea / physiology
Corneal Neovascularization / metabolism,  pathology,  prevention & control*
Disease Models, Animal*
Drug Synergism
Female
Glucocorticoids / therapeutic use
Graft Survival / drug effects*
Keratoplasty, Penetrating*
Lymphangiogenesis / drug effects
Lymphatic Vessels / drug effects,  physiology
Male
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Morpholinos / therapeutic use*
Triamcinolone Acetonide / therapeutic use
Vascular Endothelial Growth Factor A / metabolism
Vascular Endothelial Growth Factor Receptor-1 / genetics*,  metabolism
Grant Support
ID/Acronym/Agency:
NIHEY017950//PHS HHS; P30 EY014800/EY/NEI NIH HHS
Chemical
Reg. No./Substance:
0/Glucocorticoids; 0/Morpholinos; 0/Vascular Endothelial Growth Factor A; 0/vascular endothelial growth factor A, mouse; 76-25-5/Triamcinolone Acetonide; EC 2.7.10.1/Flt1 protein, mouse; EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease.
Next Document:  An ENU mutagenesis screen in zebrafish for visual system mutants identifies a novel splice-acceptor ...